Journal Article
. 2014 Jan;3().
doi: 10.3389/fonc.2013.00317.

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer

David M Marcus 1 Jeffrey M Switchenko 2 Roshan Prabhu 1 Ruth O'Regan 3 Amelia Zelnak 3 Carolina Fasola 1 Donna Mister 1 Mylin A Torres 1 
  • PMID: 24409418
  •     13 References
  •     1 citations


Objectives: We compared outcomes in post-menopausal estrogen receptor-positive (ER+) breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) or neoadjuvant chemotherapy (NACT).

Methods: We retrospectively identified post-menopausal women who received either NAHT or NACT for non-metastatic, non-inflammatory, ER+, Her2neu negative breast cancer from 2004 to 2011. We compared long-term rates of locoregional relapse free survival (LRFS), distant metastasis free survival (DMFS), and overall survival (OS) using the Kaplan-Meier method. The Cox proportional hazards model was used to identify patient and disease factors significantly associated with these endpoints.

Results: We identified 99 patients in our study, including 27 who received NAHT and 72 who received NACT. There were no differences in 4-year LRFS, DMFS, or OS between groups. On Cox proportional hazards modeling, the type of systemic therapy (NAHT versus NACT) was not associated with OS. However, patients with progesterone receptor (PR) positive disease had a 92% lower risk of death compared to patients with PR negative disease.

Conclusion: Our data suggest that outcomes are not adversely affected by NAHT in post-menopausal women with ER+ breast cancer. Therefore, NAHT is a viable and potentially less toxic option than NACT in appropriately selected patients. Furthermore, although PR negative disease appears to be associated with poor prognosis, intensification of systemic treatment with chemotherapy may not be associated with improvement of disease-related outcomes in this patient population.

Keywords: breast cancer; chemotherapy; hormonal therapy; neoadjuvant therapy; outcomes.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, +7 authors, Charles M Perou.
Clin Cancer Res, 2007 Apr 18; 13(8). PMID: 17438091
Highly Cited.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
M Kaufmann, G von Minckwitz, +16 authors, S Loibl.
Ann Oncol, 2007 Nov 14; 18(12). PMID: 17998286
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, +10 authors, Lajos Pusztai.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250347
Highly Cited.
Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.
D A Cameron, E D Anderson, +5 authors, U Chetty.
Br J Cancer, 1997 Jan 01; 76(8). PMID: 9376273    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Marjorie C Green, Aman U Buzdar, +16 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087943
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Manfred Kaufmann, Gabriel N Hortobagyi, +17 authors, Gunter von Minckwitz.
J Clin Oncol, 2006 Apr 20; 24(12). PMID: 16622270
Highly Cited.
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Vladimir F Semiglazov, Vladislav V Semiglazov, +7 authors, Lev M Berstein.
Cancer, 2007 Jun 01; 110(2). PMID: 17538978
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Nehmat Houssami, Petra Macaskill, +2 authors, Eleftherios Mamounas.
Eur J Cancer, 2012 Jul 07; 48(18). PMID: 22766518
Highly Cited.
The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
Yaling Wang, Lin He, +4 authors, Xuezhen Ma.
BMC Womens Health, 2020 Feb 02; 20(1). PMID: 32005117    Free PMC article.